JP2010502689A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502689A5
JP2010502689A5 JP2009527220A JP2009527220A JP2010502689A5 JP 2010502689 A5 JP2010502689 A5 JP 2010502689A5 JP 2009527220 A JP2009527220 A JP 2009527220A JP 2009527220 A JP2009527220 A JP 2009527220A JP 2010502689 A5 JP2010502689 A5 JP 2010502689A5
Authority
JP
Japan
Prior art keywords
compound
furan
methoxydibenzo
cyano
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/002596 external-priority patent/WO2008032171A1/en
Publication of JP2010502689A publication Critical patent/JP2010502689A/ja
Publication of JP2010502689A5 publication Critical patent/JP2010502689A5/ja
Pending legal-status Critical Current

Links

JP2009527220A 2006-09-11 2007-09-10 Pde−4およびpde−10の阻害剤としてのジベンゾフラン誘導体 Pending JP2010502689A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1647CH2006 2006-09-11
PCT/IB2007/002596 WO2008032171A1 (en) 2006-09-11 2007-09-10 Dibenzofuran derivatives as inhibitors of pde-4 and pde-10

Publications (2)

Publication Number Publication Date
JP2010502689A JP2010502689A (ja) 2010-01-28
JP2010502689A5 true JP2010502689A5 (cg-RX-API-DMAC7.html) 2010-10-21

Family

ID=38969801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527220A Pending JP2010502689A (ja) 2006-09-11 2007-09-10 Pde−4およびpde−10の阻害剤としてのジベンゾフラン誘導体

Country Status (14)

Country Link
US (1) US8263648B2 (cg-RX-API-DMAC7.html)
EP (1) EP2074106B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010502689A (cg-RX-API-DMAC7.html)
CN (1) CN101573348A (cg-RX-API-DMAC7.html)
AU (1) AU2007297221B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716804A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663178C (cg-RX-API-DMAC7.html)
IL (1) IL197507A (cg-RX-API-DMAC7.html)
MX (1) MX2009002657A (cg-RX-API-DMAC7.html)
NZ (1) NZ575389A (cg-RX-API-DMAC7.html)
RU (1) RU2009113585A (cg-RX-API-DMAC7.html)
SG (1) SG174810A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008032171A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901714B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115874A2 (en) * 2008-03-17 2009-09-24 Matrix Laboratories Ltd. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
WO2010080481A1 (en) 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
US8580795B2 (en) * 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
WO2011132051A2 (en) * 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
AR096721A1 (es) 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
SG11201510028PA (en) 2013-06-25 2016-01-28 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
KR102280686B1 (ko) 2014-02-11 2021-07-22 삼성전자주식회사 카바졸계 화합물 및 이를 포함한 유기 발광 소자
EP3180411B1 (de) * 2014-08-13 2018-08-29 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
JP6599983B2 (ja) 2014-10-24 2019-10-30 ブリストル−マイヤーズ スクイブ カンパニー カルバゾール誘導体
HUE050592T2 (hu) 2014-10-24 2020-12-28 Bristol Myers Squibb Co Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
EP3209652B1 (en) 2014-10-24 2020-04-15 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
CA3005727A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
CR20180374A (es) 2015-12-22 2018-10-16 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CR20190318A (es) 2016-12-22 2019-10-21 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7303108B2 (ja) 2016-12-22 2023-07-04 インサイト・コーポレイション 免疫調節剤としての二環式複素芳香環化合物
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
CN108084128B (zh) * 2017-12-28 2020-01-03 福建中医药大学 一种二苯并呋喃衍生物及其制备方法和用途
EP4212529B1 (en) 2018-03-30 2025-01-29 Incyte Corporation Heterocyclic compounds as immunomodulators
CN110407741B (zh) * 2018-04-26 2023-03-21 启元生物(杭州)有限公司 一种抗炎化合物及其制备和应用
EP4520328A3 (en) 2018-05-11 2025-04-16 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CR20220190A (es) 2019-09-30 2022-06-15 Incyte Corp Compuestos de pirido [3,2-d] primidina como inmunomoduladores
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506379A (ja) * 2002-10-23 2006-02-23 グレンマーク・ファーマシューティカルズ・リミテッド 炎症性およびアレルギー性疾患の治療に有用な新規三環式化合物:その調製方法およびそれらを含む医薬組成物
WO2004089940A1 (en) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004111044A1 (en) * 2003-06-17 2004-12-23 Glenmark Pharmaceuticals Ltd. Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation
WO2006011024A2 (en) * 2004-07-19 2006-02-02 Glenmark Pharmaceuticals Ltd. New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2006051390A1 (en) * 2004-11-10 2006-05-18 Glenmark Pharmaceuticals S.A. Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, pharmaceutical compositions containing them, and methods of preparing them
AP2334A (en) * 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.

Similar Documents

Publication Publication Date Title
JP2010502689A5 (cg-RX-API-DMAC7.html)
RU2009113585A (ru) Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
JP6598974B2 (ja) B型肝炎ウイルス感染症の治療および予防のための新規な三環式4−ピリドン−3−カルボン酸誘導体
US8829190B2 (en) Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
JP6298998B2 (ja) ウイルス感染を治療するための1,2,4−トリアジン誘導体
AU2012342547C1 (en) Method for producing substituted 5-fluoro-1H-pyrazolopyridines
EP2693876B1 (en) Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
ZA200603474B (en) Alkoxy substituted imidazoquinolines
CA3167023A1 (en) Sulfonimidamide compounds as nlrp3 modulators
RU2010147404A (ru) Замещенные дигидропиразолоны в качестве ингибиторов hif-пролил-4-гидроксилазы
WO2017016530A1 (en) A method for preparing methyl (z)-3-[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl] amino]phenyl]amino]phenylmethylene)-oxindole-6-carboxylate (intedanib, nintedanib)
JP2002088073A (ja) 抗アンドロゲン剤
JP2013529602A (ja) ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物
JP2017524742A (ja) テトラヒドロキノリン誘導体の調製のための合成中間体の調製方法
JP2017522339A (ja) 2−アミノ−ベンゾイミダゾール誘導体ならびにこれらの5−リポキシゲナーゼおよび/またはプロスタグランジンeシンターゼ阻害剤としての使用
US9567333B2 (en) Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2022033380A1 (zh) 一种mor受体激动剂化合物、制备方法及其用途
JPWO2001021206A1 (ja) NF−κB阻害剤を有効成分とする心筋炎、拡張型心筋症および心不全の予防または治療薬
WO2011002103A2 (en) A cycloalkane derivative
CA2879816C (en) Methanethione compounds having antiviral activity
JP2022505827A (ja) 置換インドール二量体の化合物
US20080161419A1 (en) Prophylactic Antimigraine Agents
JP2008526818A (ja) Pde10インヒビターとしての新規のピロロジヒドロイソキノリン
JP2018043989A (ja) ブロナンセリンを製造する方法
JP5836360B2 (ja) 1‐シクロプロピル‐8‐メチル‐7‐[5‐メチル‐6‐(メチルアミノ)‐3‐ピリジニル]‐4‐オキソ‐1,4‐ジヒドロ‐3‐キノリンカルボン酸塩